Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Geriatrics | Internal Medicine | Neurology | Nursing | Pathology | Psychiatry | Journal

Back to Journal Articles

Alzheimer’s Cognitive Decline Slows in Advanced Age

Last Updated: August 03, 2012.

 

Increasing cognitive decline for cognitively healthy results in convergence of several measures

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
The rates of cognitive decline and atrophy characteristic of Alzheimer's disease decrease with advancing age, while cognitively healthy individuals show increased rates, according to a study published online Aug. 2 in PLoS One.

FRIDAY, Aug. 3 (HealthDay News) -- The rates of cognitive decline and atrophy characteristic of Alzheimer's disease (AD) decrease with advancing age, while cognitively healthy individuals show increased rates, according to a study published online Aug. 2 in PLoS One.

Dominic Holland, Ph.D., of the University of California in San Diego, and colleagues evaluated the rate of change in cognitive function and atrophy in specific regions of the brain measured using magnetic resonance imaging. Participants included 723 adults aged 65 to 90 years with AD or mild cognitive impairment (MCI), or who were cognitively healthy.

The researchers found that, as people aged, the rate of cognitive decline and atrophy slowed down substantially for those with AD and MCI but increased for those who were cognitively healthy at baseline. For several measures there was a convergence in the rates of change for patients and cognitively healthy controls with advancing age. The cerebrospinal fluid density of several AD-related proteins, particularly phospho-tau181p, converged with advancing age

"These results imply that the phenotypic expression of AD is relatively mild in individuals older than approximately 85 years, and this may affect the ability to distinguish AD from normal aging in the very old," the authors write. "Our findings show that inclusion of older individuals in clinical trials will substantially reduce the power to detect disease-modifying therapeutic effects, leading to dramatic increases in required clinical trial sample sizes with age of study sample."

Several authors disclosed financial ties to CorTech Labs Inc. Data collection was funded by the Alzheimer's Disease Neuroimaging Initiative, which is funded by the pharmaceutical industry.

Abstract
Full Text

Copyright © 2012 HealthDay. All rights reserved.


Previous: Lack of Sleep Affects Speed, Not Accuracy of Visual Tasks Next: Gene Subnetworks Predict Risk of Leukemia Progression

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2013
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.